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RabbitAbstract Ophthalmic drug bioavailability is limited due to protective mechanisms of the eye which
require the design of a system to enhance ocular delivery. In this study several liposomal formula-
tions containing ciproﬂoxacin (CPX) have been formulated using reverse phase evaporation
technique with ﬁnal dispersion of pH 7.4. Different types of phospholipids including Phosphatidyl-
choline, Dipalmitoylphosphatidylcholine and Dimyristoyl-sn-glycero-3-phosphocholine were uti-
lized. The effect of formulation factors such as type of phospholipid, cholesterol content,
incorporation of positively charging inducing agents and ultrasonication on the properties of the
liposomal vesicles was studied. Bioavailability of selected liposomal formulations in rabbit eye
aqueous humor has been investigated and compared with that of commercially available CPX
eye drops (Ciprocin). Pharmacokinetic parameters including Cmax, Tmax, elimination rate con-
stant, t1/2, MRT and AUC0–1, were determined. The investigated formulations showed more than
three folds of improvement in CPX ocular bioavailability compared with the commercial product.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Ciproﬂoxacin, a ﬂuoroquinolone antibacterial agent, is active
against a broad spectrum of aerobic gram-positive and gram-
negative bacteria. It is currently the drug of choice as an
anti-infective agent for the eye (Wilhelmus et al., 1993). The
antibacterial efﬁciency of CPX results from inhibiting two
enzymes involved in bacterial DNA synthesis leading to rapid
bacterial cell death. The interaction between CPX and bacte-
rial pathogen is not located in the blood stream but in periph-
eral tissues. Thus, effective antimicrobial therapy is dependent
upon the delivery of sufﬁciently high drug concentrations to
the target site of infection in order to inhibit bacterial growth
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1989). Efﬁcacy of the marketed ophthalmic ﬂuoroquinolone
products, mostly aqueous solutions, is limited by poor ocular
bioavailability, (Ludwig, 2005; Ke et al., 2010). Ciproﬂoxacin
eye drops, which are available presently, need to be adminis-
tered as 1–2 drops every 15–30 min initially in acute infection
and 1–2 drops to be administered 6 times daily or more in se-
vere conditions (Mundada and Shrikhande, 2008). It is known
that CPX is the least soluble of the commercially available ﬂu-
oroquinolones, with particularly low solubility near the pH of
tears (pH 7) (Ross and Riley, 1990). The formation of crys-
talline corneal deposits indicates a decrease in the concentra-
tion of drug dissolved in the tear ﬁlm and, consequently, a
potential decrease in drug bioavailability. Additionally, the
presence of deposits in the tear ﬁlm creates safety concerns
(Wilhelmus and Abshire, 2003). Ophthalmic CPX commercial
eye drop solutions are the most acidic (pH 4.5), which lead to
local burning, irritation, itching and tearing.
Vesicular drug delivery systems such as liposomes have
been used in therapeutic approaches for ocular abnormalities.
Efﬁcacy of liposomes as a carrier for drugs depends upon var-
ious factors such as charge, rigidity, composition of the liposo-
mal membrane, encapsulation efﬁciency and release rate (Lee
et al., 1985). It was reported that positively charged liposomes
have a higher binding afﬁnity to the corneal surface than neu-
tral and negatively charged vesicles as a result of interaction of
positively charged liposomes with the polyanionic corneal and
conjunctival mucoglycoprotiens. It is known that the corneal
epithelium is thinly coated with negatively-charged mucin to
which the positive surface charge of the liposomes may be ab-
sorbed more strongly. This makes the study of positively
charged liposomes necessary for optimizing CPX liposomal
formulations with prolonged effect and for treating the interior
eye tissues (El-Gazayerly and Hikal, 1997).
The aim of this study was to formulate liposomal colloidal
dispersions of various compositions. The effect of formulation
factors such as type of phospholipid, ratio of cholesterol con-
tent, presence of positive charging agent and ultrasonication
on the characteristics of the liposomal vesicles was evaluated.
Ocular bioavailability of CPX in rabbit eyes has been investi-
gated using selected liposomal formulations and compared
with a commercially available CPX eye drops (Ciprocin).
This was achieved by monitoring CPX in rabbit eye aqueous
humor. Enhanced ocular bioavailability of CPX, thus, could
be useful to improve the treatment of infected eye and preven-
tion of post-surgical infection.2. Materials and methods
2.1. Materials
Ciproﬂoxacin (CPX) was obtained from FlukaBiochemika,
Buschs, Switzerland. Soybean L-a–Phosphatidylcholine(PC),
L-a–Dipalmitoyl-phosphatidylcholine(DPPC), 1,2-Dimyri-
stoyl-sn-glycero-3-phosphocholine (DMPC), Stearylamine(SA),
Dioctadecyldimethylammonium bromide (DODAB) and Cho-
lesterol (CH)were obtained fromSigma–Aldrich,USA.Chloro-
form was purchased from BDL laboratory Ltd., Poole,
England, UK. All solvents used in chromatographic assay were
HPLC-grade and other used chemicals and solvents werecommercially available products of reagent grade and used as
received.
2.2. Methods
2.2.1. High performance liquid chromatography (HPLC) assay
of ciproﬂoxacin
A simple and highly sensitive isocratic reversed-phase high-
performance liquid chromatographic method (RP-HPLC) pro-
posed by Zotou and Miltiadou (2002) has been modiﬁed to be
used for the determination of CPX. Shimadzu HPLC system
consists of Intelligent HPLC pump, model no. LC-10ADVP
and Rheodyne sample injector with 20 ll, model no. LC-SIL
10ADVP, Shimadzu Corporation, Japan have been used in
the analysis. The mobile phase consisted of acetonitrile: meth-
anol: acetate buffer (pH 3.6; 0.05 M) (10:20:70 v/v) containing
1% (v/v) acetic acid. The mobile phase was freshly prepared on
each day of analysis, ﬁltered through 0.45 lm Millipore ﬁlter
and degassed. Separation of ciproﬂoxacin and anthranilic acid
(Internal Standard) was achieved on a Kromasil 100, C18,
5 lm (250 · 4.6 mm i.d.) reversed-phase column(phenomenex,
USA), using ﬂuorescence detection(Fluorescence detector,
model no. RF-10AXL, Shimadzu Corporation, Japan) with
kexc = 300 nm and kemi = 458 nm. The operating temperature
was ambient, with a ﬂow rate of 0.8 ml/min.
2.2.2. Preparation of ciproﬂoxacin liposomes
Liposomal vesicles containing CPX were prepared using the
reverse evaporation technique (REV) as described by Szoka
and Papahadjopoulos (1978). Table 1 represents the molar
ratios of the lipid components used in the different liposomal
formulations with total lipid concentration of 66 lmol/ml for
each formulation. The lipid components were weighed and
dissolved in 15 ml chloroform. The solution was then trans-
ferred to a 250 ml round-bottomed ﬂask. An aliquot of
5 ml isotonic phosphate buffer of pH 4.5 containing CPX
was added to the chloroform mixture. The chloroform was
then removed by rotary evaporation at 40 C (Rotatory evap-
orator }bchirotavapor model no. R210 from Labortechnik AG
and vacuum pump model no. V-700 }Bchi, Flawil, Switzer-
land). The liposomal dispersion was then centrifuged at
30,000 rpm and 4 C for 45 min (Centrifuge model no. D-
7200 from Hitachi Company New Zealand). Supernatant
was carefully removed and assayed for its free CPX content
while the liposomal pellets were re-dispersed in isotonic phos-
phate buffer pH 7.4. The liposomal dispersions were then al-
lowed to equilibrate at room temperature and kept overnight
at 4 C (Monem et al., 2000; Li et al., 1998; Gu¨rsoy and
Senyu¨cel, 1997).
2.2.3. In-vitro evaluation of liposomal vesicles
2.2.3.1. Particle size and particle size distribution. The mean
particle size and polydispersity index for each liposomal for-
mula were determined by photon correlation spectroscopy
using 90 Plus particle size analyzer, (Laser nanoparticle size
analyzer model no. 90 Plus- software version 3.74, Brookhaven
Instruments, Holtsville, New York, USA). The polydispersity
index was used as a measure for particle size distribution of
the liposomal vesicles’ population. Liposomal dispersions were
diluted 10 times with isotonic phosphate buffer pH 7.4 before
Table 1 Composition of CPX liposomal formulation (in molar ratio).
Formulations No. Phospholipid component CH SA DODAB
PC DPPC DMPC
F1 1 – – – – –
F 2 1 – – 1 – –
F 3 2 – – 1 – –
F 4 7 – – 1 – –
F 5 7 – – 1 2 –
F 6 7 – – 1 – 2
F 7 – 1 – – – –
F 8 – 1 – 1 – –
F 9 – 2 – 1 – –
F 10 – 7 – 1 – –
F 11 – 7 – 1 2 –
F 12 – 7 – 1 – 2
F 13 – – 1 – – –
F 14 – – 1 1 – –
F 15 – – 2 1 – –
F 16 – – 7 1 – –
F 17 – – 7 1 2 –
F 18 – – 7 1 – 2
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lue is the average of three measurements.
2.2.3.2. Determination of entrapment efﬁciency (EE%) of CPX
in liposomes. The entrapment efﬁciency is deﬁned as the ratio
of the amount of the CPX encapsulated in liposome to that
of the total drug in liposomal dispersion (Guard et al.,
2007). The initial liposomal dispersions were centrifuged at
30,000 rpm and 4 C for 45 min to remove the non-encapsu-
lated drugs. The concentrations of CPX in the supernatant
representing the amount of CPX out of the liposomal vesicles
were determined using HPLC assay method.
The EE% of CPX was calculated as follows:
EE% ¼ ðMtMf=MtÞ  100
where: Mf and Mt represent the free CPX amount and total
CPX amount, respectively.
The EE% was determined to evaluate the effect of changing
liposomal composition and ultrasonication on the properties
of liposomes (Budai et al., 2007).
2.2.3.3. Effect of ultrasonication on the characteristics of
liposomal vesicles. Ultrasonic homogenizer SONOPULS HD
2070 (Germany); with titanium ﬂat tip probe of diameter
6 mm and processing frequency 20 kHz with 70 W power has
been used. The liposomal sample was held within quartz glass
cell. The volume of the sample solution was 3 ml. The quartz
cell was ﬁxed to the body of ice bath. The distance between
the top of the sonication probe and the bottom of the quartz
cell was kept constant (10 mm). The samples were sonicated
at 25%, 50%, 75% and 100% of power 70 W for one minute
to test the effect of sonication power on liposomal vesicle
properties. The effect of sonication time for 0.5, 1, 1.5 and
2 min at 50% of power 70 W was also tested.
2.2.3.4. In vitro CPX release studies. In vitro release of CPX
liposomes was performed by applying the dialysis diffusion
technique (Avgoustakis et al., 2002), using the dissolution test
apparatus USP II (Dissolution apparatus from Erweka DT, 6Germany). Artiﬁcial tears of pH 7.4 (Paulsson et al., 1999)
were used as the dissolution medium. The dialysis method
was applied using cellulose acetate dialysis membrane of
12,000–14,000 molecular weight cut off (Dialysis sac molecular
weight cut-off 12,000–14,000, Spectra Por Dialysis mem-
brane, Spectrom Medical Industries, Inc., USA). This mem-
brane assures the permeation of the drug with retention of
liposomal vesicles. The membrane was soaked in artiﬁcial tears
for 12 h before use. Four ml of liposomal dispersion was placed
in a glass cylinder having a length of 8 cm and diameter of 1 cm
and dialysis membrane was ﬁxed to opening of glass cylinder
by a thread. Each glass cylinder was attached to the shaft of
the dissolution apparatus (USP Dissolution tester) and des-
cended down into a 50 ml beaker containing 10 ml of artiﬁcial
tears as dissolution medium without touching the bottom sur-
face of the beaker. The beakers were then placed into vessels of
dissolution apparatus that contained about 100 ml of water to
keep temperature at 34 ± 0.5 C. The glass cylinders were ad-
justed to rotate at a constant speed of 20 rpm (Hosny, 2010).
One ml of dissolution medium was withdrawn at predeter-
mined time intervals (0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,
5.5, 6, 6.5, 7, 7.5 and 8 h).The samples were replaced with fresh
dissolution medium to maintain constant volume. Drug con-
centrations in samples were analyzed using the HPLC method
as described previously. The release experiments were carried
out in triplicates and the mean ± SD were recorded.2.3. In-vivo evaluation
2.3.1. Animal
Male New Zealand white Albino rabbits were selected as the
model animal for in vivo study. The rabbits (weighed 2–
2.5 kg) were free of any gross ocular defects. The rabbits were
starved for 24 h before allowed to free access to water. Proce-
dures involving animals were conducted in accordance with
US guidelines as found in the NIH Guide for the Care and
Use of Laboratory Animals (NIH Publication No. 18–23,
1985). Animals were maintained in accordance with the recom-
Table 2 Physical characterization of liposomal formulations.
Formulation
no.
Particle
size (ng)
Polydispersity Entrapment
Eﬃciency %
(EE %)
F1 461 ± 28 0.167 44.7
F 2 512 ± 84 0.203 39.6
F 3 495 ± 21 0.247 40.6
F 4 442 ± 10 0.275 42.5
F 5 528 ± 36 0.247 40.6
F 6 530 ± 25 0.278 41.9
F 7 420 ± 25 0.150 42.2
F 8 788 ± 121 0.165 37.3
F 9 572 ± 33 0.147 39.6
F 10 542 ± 41 0.181 39.9
F 11 576 ± 52 0.205 40.3
F 12 619 ± 71 0.237 39.4
F 13 580 ± 197 0.940 40.2
F 14 1047 ± 41 0.139 36.4
F 15 925 ± 127 0.005 38.4
F 16 748 ± 12 0.128 40.5
F 17 772 ± 103 0.024 39.1
F 18 769 ± 139 0.171 38.2
234 E.I. Taha et al.mendations in King Saud University Guide for the Care and
Use of Laboratory Animals, approved by Animal Care and
Use Committee.
2.3.2. Study design
Three liposomal formulations were selected for in vivo evalu-
ation, namely F6, F12 and F13. Bioavailability test was done
after sonication of the three formulations (F6, F12 and F13)
for one minute using sonication power of 25%. The ﬁnal
particle sizes were 387, 388 and 410 for F6, F12 and F13
respectively. While EE% was 39.6, 37.1 and 36.7 for F6, F12
and F13 respectively. The selection of these formulations based
on deferent lipid content, presence of positive charge inducing
agent as well as the higher entrapment efﬁciency with the
smallest possible particle size for DMPC. The dose of aliposo-
mal formulation was dropped in the right eye while the com-
mercial 0.3% ciproﬂoxacin solution Ciprocin (Riyadh
pharma, Riyadh, Saudi Arabia) was dropped in the left eye.
The restricted dose volume of 50 ll was placed in the lower
conjunctival sac, approximately midway between the inner
and outer canthus. For each formulation, the animal was
killed after taking a sample from eye aqueous humor at each
of the following time intervals: 0, 0.5, 1, 2, 3, 4 and 5 h post
installation. The samples were withdrawn, by paracentesis with
a 23 gauge 1.25 cm needle attached to 1 ml syringe inserted
through the corneal-scleral junction and slightly upward into
the anterior chambers. All animals in the study conformed
to the guidelines for animal experimentation in the King Saud
University. The aqueous humor samples (200 ll each) were
immediately centrifuged at 20,000 rpm and 4 C for 20 min.
The supernatant was then collected and frozen at 20 C
pending assay. Samples were suitably diluted with mobile
phase and an aliquot of 20 ll of resultant solution was directly
injected into the HPLC system.
2.3.3. Pharmacokinetic analysis
The pharmacokinetic parameters were calculated from the
data of analysis of CPX level in rabbit aqueous humor samples
and presented as mean ± SD. Maximum CPX aqueous humor
concentration (Cmax) and the time to reach this maximum
(Tmax) were determined. The total area under the aqueous
humor concentration–time curve (AUC0–5, lg.min/ml) and
the area under the ﬁrst momentum curve (AUMC0–5) up to
the last time point were estimated based on the trapezoidal
rule. The area of the tail was calculated using the aqueous
humor concentration at the last time point and the terminal
elimination rate constant (k). The value of k from aqueous
humor was estimated from the least square regression analysis
of the ﬁnal segment of the curve. The mean residence time
(MRT) values were calculated as the ratio of the calculated
AUMC0–1 to AUC0–1 in each case. The rate of absorption
was also calculated using the relation Cmax/AUC0–1. Relative
bioavailability (RB) was measured by comparing bioavailabil-
ity of formulation with that of the commercial product
(Ciprocin).
3. Statistical analysis
One- way analysis of variance (ANOVA) with multiple com-
parisons was performed to test for signiﬁcance. The pharmaco-kinetic parameters were subjected to ANOVA at a signiﬁcant
level of P 6 0.05.
4. Results and discussion
4.1. Effect of type of phospholipids on particle size and EE% of
CPX Liposomes
The average particle size of liposomal vesicles is an important
parameter with respect to physical properties, biological fate
and their drug entrapped property. Table 2 shows the effect
of type of phospholipids on mean particle size and particle size
distribution. Generally, all liposomal preparations showed
small particle in the colloidal range. It was clear that DPPC
gave the smallest particle size compared with PC and DMPC
and this was in agreement with Lo´pez-Pinto et al. (2005).
DMPC phospholipid gave the largest particles which were also
characterized by large particle size distribution as indicated
from standard deviation and polydispersity index values.
Table II shows also the values of EE% for CPX of liposomes
prepared with different types of phospholipids. The results indi-
cated that the highest EE%was obtained for PC compared with
DPPC and DMPC formulations. It can be concluded that the
EE% was enhanced by increasing the number of carbons in
the branched leaving group of phospholipids. Liposomes for-
mulated with PCmolecules containing 42 carbon atoms showed
44.7 EE% while, DPPC of 40 carbon atoms showed 42.2 EE%
and DMPC of 36 carbon atoms showed the least value of 40.2
EE%. Thus, a correlation between EE% and chain length of
phospholipid present in the lipid formulation was observed.
The values of EE% were found to be in a descending order as
follows: PC (No. of Carbons = 42) > DPPC (No. of car-
bons = 40) > DMPC (No. of carbons = 36). Similar results
were obtained by Ravivarapu and White (1996), McIntosh
(1978), Gulati etal. (1998) for both water soluble and insoluble
drugs. They observed that entrapment in liposomes increased
with an increase in the carbon chain length of PC employed.
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CPX liposomes
Cholesterol is the most common membrane additives found in
vesicular systems. It is important to study the effect of CH on
physical properties of liposome since CH inﬂuences a number
of membrane properties such as ion permeability, aggregation,
fusion processes, elasticity, size and shape. Inclusion of CH in
membrane increases the rigidity of the bilayer and reduces the
leakage of water soluble substances through membranes.
The effect of CH concentration on average particle size of
CPX liposome was studied at different phospholipid:CH mo-
lar ratios (Tables 1 and 2).The results indicated that, generally,
liposome particle size increases linearly with the increase of
CH concentration. It is well accepted that incorporation of
CH imparts rigidity to the bilayer membranes; thus, improve
the physical stability for liposomal systems (Taylor et al.,
1990; Essa, 2010).
On the other hand, the encapsulation parameters depend
on the ﬂuidity of the phospholipid bilayer. The lower the ﬂuid-
ity, the greater is the encapsulation capacity. The ﬂuidity of
bilayers can be controlled by selection and combination of lip-
ids. Increasing EE% in the absence of CH could be due to the
fact that CH increases the hydrophobicity of the interfacial re-
gion of the bilayers (Abdelbary, 2011) which is not in favor of
the entrapment of CPX at the acidic pH during the formation
of liposomal vesicles.
It is worthy also to mention that incorporation of CH at
low concentrations into bilayer leads to an increase in the
trans-membrane permeability, whereas incorporation of higher
amounts of CH to some extent can eliminate phase transition
and decrease the membrane permeability (Lian and Ho, 2001).
These results are also in good agreement with Abdelbary
(2011) who studied improvement of the ocular bioavailability
of CPX through the preparation of ocular mucoadhesive
chitosan coated liposomes. The increase in CH molar concen-
tration resulted in a signiﬁcant decrease in EE%. This conﬁrms
that the presence of high concentrations of CH is not in favor
of CPX entrapment (Abdelbary, 2011). Thus, the effect of CH0
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Figure 1 Effect of sonication power (applied for 1concentration on EE% of CPX can be explained by conﬂicting
factors which are the increased hydrophobicity and decreased
permeability of the bilayer (Mohammed et al., 2004).
4.3. Effect of introducing positive charge on particle size and
EE% of CPX liposomes
Charged molecules are additives which are often included in
the liposomal bilayer structure with the aim of improving sta-
bility via electrostatic means. Using a charge-inducing agent
let all liposomes to carry the same electrical charge which pro-
duces electrostatic repulsion between liposome vesicles, thus
making liposomes to remain discrete and preventing vesicle
ﬂocculation, aggregation and fusion. Moreover, preparing
charged vesicles was sometimes aimed to improve the thera-
peutic efﬁciency of vesicles, as charged liposomes were found
to be selectively taken by certain tissues in the body including
the eye cornea.
Retention of liposomes on the cornea1 surface perhaps rep-
resents the major challenge for effective ocular drug delivery.
Several studies have shown that introducing a positive surface
charge on vesicles can prolong precorneal retention time, en-
hance ocular bioavailability and ultimately augment or increase
the duration of pharmacological effect. Liposomes with a posi-
tive surface charge may form a more stable adsorption because
cornea1 epithelium is thinly coated with negatively charged mu-
cin. Most studies have used SA to impart a positive surface
charge to liposomes (Meisner and Mezei, 1995).
Both SA and DODAB can be used as charge-inducing
agents to impart a positive charge to the liposomes’ surface.
At 7:1:2 M ratio of phospholipid:CH:SA or DODAB, the ef-
fect of charge on the particle size of liposome was studied com-
pared with uncharged liposome as control. It was clear that
positively charged liposomes formulated from different phos-
pholipids have a mean particle diameter larger than that of
neutral liposomes. The effect of inclusion of charged molecules
into bilayers with an increase of particle size was in agreement
with previous studies (Van Hal et al., 1996). The developed
charge could create mutual repulsion between liposome bilay-F10 F11 F12 F13 F14 F15 F16 F17 F18
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structure of the ionized species affected the extent of size
enlargement. Generally, DODAB showed a non-signiﬁcant in-
crease in particle size compared with SA for PC and DPPC
and this was not clear for DMPC.
It was also observed that the presence of charge inducing
agent decreases to a little extent the leakage of CPX from
the liposomes compared with neutral liposomes as indicated
from the small decrease in EE% values at the used ratio of
the charging agents.
4.4. Effect of sonication power and time on the particle size and
EE% of CPX liposomes
Figs. 1 and 2 show the effect of sonication power and sonica-
tion time, on CPX liposomal vesicle particle sizes. It was clear
that % sonication power (at 70 W) has a great effect on lipo-
somal particle size. Particle sizes were decreased upon ultra-
sonication and this effect was high after sonication power of
25%. On the other hand, a gradual decrease in particle size
was observed with increasing sonication time (at 50% power)
up to 1.5 min. It was also noticed that increasing sonication
time more than 1.5 min did not show a signiﬁcant effect on
particle size in many cases. In addition, the presence of CH
may retard the decrease in particle size. The increase of vesicle
rigidity in the presence of CH could be the reason for this
observation.
On the other hand, the effect of % of sonication powers ap-
plied for 1 min on the encapsulation efﬁciency is shown in
Fig. 3. The results demonstrated that the encapsulation efﬁ-
ciency decreased with increasing sonication power. This could
be because sonication can interrupt the packing of liposomal
structure and this interruption is great at high sonication
power. Also, with the increase of sonication power, the de-
crease of encapsulation efﬁciency may be attributed to the high
input of energy so that the liposomes from multilamellar vesi-
cles turned to unilamellar vesicles and some amount of CPX
was leaked from vesicles (Lasic, 1993).
It was also observed that the high cholesterol content of lip-
osomes can resist CPX leakage with recorded high EE% as
shown with formulae F2, F8 and, F14. This was also clear even
at high sonication power. The high EE% in the presence of CH
was attributed to the ability of CH to cement the leaking space
in the bilayer membranes, which in turn allowed enhanced core
material levels inside the liposomes (Ding et al., 2009).
The values of EE% for CPX in different liposomal formu-
lations after sonication for different times at 50% sonication
power are also shown in Fig. 4. It was observed that EE%
was decreased with increasing sonication time from 0.5 to
2 min. The presence of CH clearly resists the leakage of CPX
from liposomal structure upon sonication for some time. It
was also noticed that the presence of charge inducing agent de-
creases to small extent the leakage of CPX from the liposomes
upon sonication compared with neutral liposomes as indicated
from EE% values. However, this was not conﬁrmed in all
cases.0 1 2 3 4 5 6
Time (hr)
Figure 6 Concentrations of CPX from different liposomal
formulations in rabbit aqueous humor as well as the commercial
CPX.4.5. In vitro release study
The percent cumulative amounts of CPX released as a function
of time from liposomes formulated with different phospholip-ids are illustrated in Fig. 5 (A–C). The release study was con-
ducted in artiﬁcial tears at 34 C to represent eye surface
environment in vivo. All the liposomal formulations of differ-
ent compositions showed a small initial burst followed by
gradual CPX release. The slowest drug release was observed
Table 3 Pharmacokinetic parameters of CPX in aqueous humor following topical application of 50 ll of various liposomal
formulations and commercial CPX solution.
Parameters F6 F12 F13 Commercial CPX
Dose (lg) 114.52 107.63 109.9 150
Tmax(hr) 2 2 2 2
Cmax(lg/ml) 3.87 ± 0.217 3.66 ± 0.144 3.56 ± 0.177 2.68 ± 0.053
K (h1) 0.192 ± 0.040 0.186 ± 0.068 0.154 ± 0.033 0.36 ± 0.060
t1/2 3.77 ± 0.781 4.03 ± 1.120 4.716 ± 1.170 1.96 ± 0.312
MRT (h) 3.69 ± 0.114 3.81 ± 0.225 3.90 ± 0.155 2.92 ± 0.097
AUC0–1 (lg h/ml) 28.3 ± 2.460 28.27 ± 5.440 30.29 ± 4.270 12.05 ± 0.534
Relative bioavailability 3.1 3.3 3.4 –
238 E.I. Taha et al.for liposomal formulations containing DPPC followed by that
containing PC.
It was also noticed that the in vitro CPX release from lipo-
somal formulations is dependent on CH contents. The increase
in CH resulted in a decrease in the amount of CPX release in
8 h from the prepared liposomes. The rigidity of liposomal
vesicles in the presence of CH could be the reason for the slow
release of CPX at high CH concentrations. The same ﬁndings
were obtained by Abdelbary where, slow release of CPX was
obtained at a high content of CH [26]. It seems also that
charging agents have no appreciable effect on the CPX release
rate from the prepared formulations.4.6. Bioavailability study
Albino rabbit eye has the property that it simulates an adult
human eye with respect to size, shape, physiology, and compo-
sition of tears and was chosen as the model animal for the
study. Fig. 6 shows CPX aqueous humor concentration versus
time curve for the selected formulations compared with the
commercial product Ciprocin. Table 3 shows the pharmaco-
kinetic parameters of liposomal formulations as well as com-
mercial eye drops (Ciprocin). Maximum aqueous humor
concentration (Cmax) was achieved (3.87 lg/ml) from F6 while
Cmax for F12 and F13 were 3.66 and 3.56 lg/ml, respectively
compared with 2.68 lg/ml for Ciprocin. Time to reach max-
imum concentration (Tmax) showed no signiﬁcant differences
between formulations (p> 0.05), their values were 2 h in all
cases. The values of AUC0–1 for liposome formulations F13,
F6, and F12 were 30.29, 28.30 and 28.27 lg min/ml, respec-
tively, which were signiﬁcantly higher (p< 0.05) than that ob-
tained for commercial eye drops (AUC0–1= 12.05 lg min/
ml). These values conﬁrmed a superior ocular bioavailability
of CPX when applied as drops to the eye in the form of lipo-
somes compared with the commercial eye drops.
Table 3 shows signiﬁcant differences between the values of
Cmax, t1/2, AUC0–1 and MRT for liposome formulations and
commercial product in favor of liposomes. While, there was no
signiﬁcant difference found between the selected formulations
regarding Cmax, AUC0–1 and MRT. The increase in the values
of AUC0–1 indicates a high extent of drug absorption through
the cornea of the eye. The larger value of t1/2 for liposomal for-
mulations compared with that of the commercial may indicate
longer time for the disappearance of CPX from aqueous hu-
mor. This was also supported by the signiﬁcant high values
for MRT which indicates an enhanced residence time of the
drug in the eye. The rate of absorption of CPX from all lipo-somal formulations was signiﬁcantly higher than that of com-
mercial product (p< 0.05) indicating a higher absorption rate
through the eye tissues including cornea. It was also clear that
the selected liposomal formulations have signiﬁcant higher
bioavailability compared with the commercial products as
indicated from the relative bioavailability. The relative bio-
availability for the liposomal formulations compared with
the commercial formulation (Ciprocin) can be arranged in
a descending order as follows: F13 with relative ocular
bioavailability of 3.4 > F12 with relative bioavailability of
3.3 > F6 with relative bioavailability of 3.1. Thus, all the
tested liposomal formulations showed improved CPX ocular
bioavailability for more than three folds compared with the
commercial eye drops.
5. Conclusion
Based on the determined pharmacokinetic parameters for ocu-
lar bioavailability of CPX (Cmax, Tmax, t1/2 and AUC0–1, rate
of absorption and MRT) using aqueous humor CPX assay
data, the selected liposomal colloidal formulations showed a
signiﬁcant improvement in ocular bioavailability of CPX com-
pared with the commercial aqueous solution (Ciprocin). This
ﬁnding reveals that the application of the selected dosage
forms can improve CPX ocular bioavailability due to mini-
mum loss of the applied dose due to minimum lacrimation
(pH 7.4), enhanced residence time of the drug in the eye, and
more prolonged effect in addition to higher chance for corneal
penetration of the drug encapsulated in liposomal carrier. Fur-
thermore, the advantages of less drug to be applied on the eye
(small CPX dose) with more chance for drug penetration
through the cornea to the inside tissue of the eye should be
considered. Thus, the proposed dosage forms have more abil-
ity to treat the surface of the eye as well as internal tissues that
may be needed in post-operative cases.Acknowledgements
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